Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Exclusion Criteria

• •You cannot be grouped if you meet any of the following:
• •1. Patients who had not received trastuzumab, chemotherapy and endocrine therapy before;
• •2. Patients with central nervous system metastasis and clinical symptoms;
• •3. Patients with visceral crisis;
• •4. Patients who were considered suitable for chemotherapy by the researchers;
• •5. There are many factors that affect drug administration and absorption, such as dysphagia, chronic diarrhea and intestinal obstruction.
• •6. Patients who received radiotherapy, chemotherapy, endocrine therapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before enrollment.
• •7. He participated in other clinical trials within 4 weeks before enrollment.
• •8. Patients with metastatic disease received more than first-line endocrine therapy, chemotherapy or targeted therapy.
• •9. Other malignant tumors in the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma.
• •10. At the same time, they received any other anti-tumor treatment.
• •11. Those who have been known to have allergic history to the drug components of this regimen; have a history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation.
• •12. Severe heart disease or discomfort, including, but not limited to, the following: a history of heart failure or systolic dysfunction (LVEF \< 50%); high risk uncontrolled arrhythmias such as atrial tachycardia, resting heart rate \> 100bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-level atrioventricular block (i.e., mobitz) The results showed that there was no significant difference between the two groups (systolic blood pressure \> 180 mmHg and diastolic blood pressure \> 100 mmHg);
• •13. Pregnant and lactating women, fertile women with positive baseline pregnancy test.
• •14. According to the judgment of the researchers, there are some accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study.
• •15. Have a clear history of neurological or mental disorders, including epilepsy or dementia.
• •16. Any other situation in which the researcher believes that the patient is not suitable for the study, which may interfere with the accompanying diseases or conditions of the study, or have any serious medical obstacles that may affect the safety of the subjects (such as uncontrollable heart disease, hypertension, active or uncontrollable infection, active hepatitis B virus infection)